- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Expanded Access Program Established for Patients in the U.S. Who May Benefit from Investigational Therapy While Application is Under Review
Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration
Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities Late-stage AMD affects millions of people with no effective treatments currently available
Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
One-year findings support advancement into Phase 3 and include significant functional vision improvements observed in the time taken to walk through a vision-guided mobility maze at nine months
New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
Data includes several analyses from the landmark VOYAGER PAD trial, including findings in high-risk patients with critical limb ischemia (CLI) after lower-extremity revascularization (LER) XARELTO® has the potential to be the first anticoagulant in 20 years to show a benefit in patients with PAD after LER[i] The comprehensive PAD program within EXPLORER continues to generate new findings that may shift the way symptomatic and chronic patients are managed
Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
- New cilta-cel (BCMA CAR-T) data from the Phase 1b/2 CARTITUDE-1 study in relapsed or refractory multiple myeloma - New DARZALEX® (daratumumab) and DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) data across early lines of treatment in multiple myeloma and in amyloid light-chain (AL) amyloidosis - New data for bispecific antibodies talquetamab and teclistamab in relapsed or refractory multiple myeloma - New data investigating IMBRUVICA® (ibrutinib) as time-limited therapy in chronic lymphocytic leukemia (CLL) and long-term results in CLL, mantle cell lymphoma (MCL) and Waldenström’s Macroglobulinemia (WM)
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease
Application seeks approval of XARELTO® plus aspirin to reduce the risk of major thrombotic vascular events in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) XARELTO® is currently approved to reduce the risk of major cardiovascular events, like heart attack and stroke, in people with chronic PAD An estimated 20 million Americans are living with PAD, a disease often underdiagnosed and undertreated
Champions of Science: Breaking the Stigma of Mental Illness
Join us for a special virtual event celebrating the champions who are helping to eliminate stigma and improve mental healthcare in communities around the world
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
· SPRAVATO® is the first and only approved antidepressant medication shown to begin improving depressive symptoms with the first dose in this challenging to treat patient population · Approval is based on Phase 3 data showing SPRAVATO® reduced depressive symptoms in as little as four hours in some patients, with symptom improvement maintained through the four-week treatment period